Imugene Ltd has released a press release.
Azer-cel FDA IND Transferred to Imugene
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Imugene
- Imugene Closes SPP Raising $18.2 million
- Imugene PD1-Vaxx Update
- Imugene Receives Positive Feedback From FDA
- VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1
- S&P DJI Announces September 2023 Quarterly Rebalance
Later from Imugene
- Imugene B Cell & OV Platforms Featured at ESMO Congress
- Imugene Phase 1 onCARlytics CD19 virus clinical trial opens
- Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
- Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
- Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene